Table. Baseline Patient and Disease Characteristics.
| Factor | Patients, No. (%) (N = 357) |
|---|---|
| Age at ICI start | |
| Mean (SD) | 62.6 (14.2) |
| Median (IQR) | 63.7 (53.7-72.5) |
| Sex | |
| Women | 103 (28.9) |
| Men | 254 (71.1) |
| BRAF status | |
| WT | 186 (52.1) |
| Variant | 151 (42.3) |
| Unknown | 20 (5.6) |
| ECOG performance score | |
| 0 | 133 (37.3) |
| 1 | 205 (57.4) |
| ≥2 | 19 (5.3) |
| ICI type | |
| Dual agenta | 117 (32.8) |
| Single agent | 240 (67.2) |
| Prior lines of therapy | |
| 0 | 305 (85.4) |
| 1 | 42 (11.8) |
| 2 | 6 (1.7) |
| 3 | 3 (0.8) |
| 4 | 1 (0.3) |
| M category at ICI initiation | |
| M1a | 37 (10.4) |
| M1b | 55 (15.4) |
| M1c | 166 (46.5) |
| M1d | 99 (27.7) |
| Metastatic sites, No. | |
| 1 | 60 (16.8) |
| ≥2 | 297 (83.2) |
| Presence of liver metastases | |
| No | 249 (69.7) |
| Yes | 108 (30.3) |
| Presence of brain metastases | |
| No | 223 (62.5) |
| Yes | 99 (27.7) |
| Unknown | 35 (9.8) |
| LDH level | |
| Elevated, ≥240 IU/L | 92 (25.8) |
| WRL, ≤240 IU/L | 242 (67.8) |
| Unknown | 23 (6.4) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitors; IQR, interquartile range; LDH, lactate dehydrogenase; WRL, with reference limit; WT, wild type.
SI conversion: To convert LDH to microkatals per liter, multiply by 0.0167.
a
Dual-agent ICI indicates concurrent ipilimumab and nivolumab.